Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib

Table 4 Univariate and multivariate analyses of variables associated with time to treatment failure

	Univariate analysis		Multivariate analysis
	HR	P value	HR	P value	95%CI
Age (≥ 65 yr)	0.369	0.020	0.475	0.099	0.196-1.150
Initial dose (800 mg)	1.213	0.588
Early AFP response	0.630	0.24
AFP (< 100 ng/dL)	0.988	0.974
DCP (< 1000 mAU/mL)	0.711	0.363
MKI-associated HFSR	0.334	0.004	0.418	0.048	0.175-0.994
BCLC B	0.970	0.932
Hypertension	1.286	0.510
Diarrhea	0.517	0.159
Anorexia	1.652	0.175
Alopecia	0.337	0.019	0.792	0.679	0.262-2.391
Intervention by pharmacists	0.326	0.002	0.425	0.042	0.186-0.971

Early alpha-fetoprotein (AFP) response refers to a ≥ 20% improvement in AFP levels within 2 mo. BCLC: Barcelona Clinic Liver Cancer; DCP: Des-gamma-carboxy prothrombin; MKI-associated HFSR: Multikinase inhibitor-associated hand-foot skin reaction.